You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
四環醫藥:Hugel股權收購獲批,集團獨家代理樂提葆及玻尿酸產品不受影響
格隆匯 12-17 16:26
格隆匯12月17日丨四環醫藥發佈聲明稱,集團關注到12月17日的韓國新聞報導,韓國相關政府部門已批准Hugel股權收購項目,目前收購進展有待買賣雙方進一步確認。集團的韓國合作伙伴Hugel已多次向本集團確認雙方的合作關係不受影響,康橋資本亦有意向與本集團在未來加大雙方合作力度。本集團將繼續與Hugel保持密切的合作關係,以根據與Hugel訂立的獨家分銷協議於中國分銷A型肉毒毒素樂提葆(Letybo)及玻尿酸產品。尤其是,本集團與Hugel就A型肉毒毒素樂提葆(Letybo)及玻尿酸產品訂立的獨家分銷協議的條款及其項下的權利不會因Hugel股權收購項目的完成而受到影響。雙方將持續致力於將樂提葆打造為中國內地銷售前三的肉毒毒素品牌。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account